Analysts Set Oxford Biomedica plc (LON:OXB) PT at GBX 663.67

Shares of Oxford Biomedica plc (LON:OXB) have earned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is GBX 663.67.

A number of equities analysts recently commented on OXB shares. Stifel Nicolaus reissued a “buy” rating and set a GBX 950 price target on shares of Oxford Biomedica in a research note on Wednesday, March 11th. Deutsche Bank Aktiengesellschaft lifted their price objective on Oxford Biomedica from GBX 735 to GBX 800 and gave the stock a “buy” rating in a research note on Friday, January 9th.

Oxford Biomedica Trading Down 0.3%

Shares of Oxford Biomedica stock opened at GBX 635 on Wednesday. Oxford Biomedica has a twelve month low of GBX 232.50 and a twelve month high of GBX 952. The company has a quick ratio of 1.67, a current ratio of 1.89 and a debt-to-equity ratio of 322.11. The business has a 50-day moving average price of GBX 762.58 and a 200-day moving average price of GBX 664.08. The firm has a market cap of £767.54 million, a price-to-earnings ratio of -17.53 and a beta of 1.04.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.